Talofen may be available in the countries listed below.
Promazine hydrochloride (a derivative of Promazine) is reported as an ingredient of Talofen in the following countries:
International Drug Name Search
Terbinafine-Teva may be available in the countries listed below.
Terbinafine hydrochloride (a derivative of Terbinafine) is reported as an ingredient of Terbinafine-Teva in the following countries:
International Drug Name Search
1. CHLORPHENAMINE TABLETS BP 4mg
2. Alpharma Chlorphenamine Hayfever & Allergy Relief Tablets
3. Vantage Chlorphenamine Hayfever & Allergy Relief Tablets
4. ALLERcalm Allergy Relief Tablets
Each tablet contains 4mg Chlorphenamine Maleate.
Yellow uncoated tablets.
1) For the symptomatic control of all allergic conditions which are responsive to antihistamines, including hay fever, urticaria, vasomotor rhinitis, angioneurotic oedema, food allergy, drug and serum reactions, insect bites.
Posology
Adults: 1 tablet every four or six hours to a maximum daily dose of 24mg.
Not recommended for children under 12 years of age unless otherwise directed by a practitioner.
Elderly: As in adults, but the elderly are prone to confusional psychosis and other neurological anticholinergic effects.
Method of Administration
For oral administration.
Hypersensitivity to antihistamines; patients who have received therapy with MAOI's within the previous fourteen days.
In common with other drugs having anticholinergic effects, Chlorphenamine should be used with caution in epilepsy, prostatic hypertrophy, glaucoma, hepatic disease, bronchitis, bronchiectasis, thyrotoxicosis, raised intra-ocular pressure, severe hypertension or cardiovascular disease and bronchial asthma.
Chlorphenamine may have an additive effect when used concurrently with hypnotics and anxiolytics causing potentiation of drowsiness. A similar additive effect will result from concurrent usage of alcohol with Chlorphenamine. MAOI therapy intensifies the anticholinergic effects of Chlorphenamine. Chlorphenamine inhibits phenytoin metabolism and can lead to phenytoin toxicity.
The safety of Chlorphenamine in pregnancy has not been established. Chlorphenamine should therefore only be used when clearly required and when potential benefits outweigh the potential unknown risks to the foetus. Use during the third trimester may result in reactions in the newborn or premature neonates.
Small amounts of antihistamines are excreted in breast milk. Use by nursing mothers is not recommended because of the risks of adverse effects in the infant.
Antihistamines may inhibit lactation.
The anticholinergic properties of Chlorphenamine may cause drowsiness, dizziness, blurred vision and psychomotor impairment, which can seriously hamper the patient's ability to drive and use machinery.
Sedation varying from slight drowsiness to deep sleep. Inability to concentrate, lassitude, blurred vision, GI disturbances such as nausea, vomiting and diarrhoea may occasionally occur. Urinary retention, headaches, dryness of the mouth. Dizziness, palpitation, tachycardia, arrhythmias, hypotension, tightness of the chest, abdominal pain, dyspepsia, anorexia, hepatic including jaundice, thickening of the bronchial secretions, haemolytic anaemia and other blood dyscrasias infrequently occur.
Allergic reactions including exfoliative dermatitis, photosensitivity and skin reactions. Urticaria, twitching, muscular weakness and in co-ordination. Tinnitus, depression, irritability and nightmares infrequently occur.
Paradoxical excitation in children and confusional psychosis in the elderly can occur.
The effects of alcohol may be increased. Children and the elderly are more likely to experience the neurological anticholinergic effects.
The estimated lethal dose of Chlorphenamine is 25-50mg/kg body weight.
Symptoms and signs include sedation, paradoxical stimulation of the CNS, toxic psychosis, seizures, apnoea, convulsions, anticholinergic effects, dystonic reactions and cardiovascular collapse including arrhythmias.
Treatment includes gastric lavage or emesis using ipecacuanha syrup. Following these measures activated charcoal and cathartics may be administered to minimise absorption. Other symptomatic and supportive measures should be provided with special attention to cardiac, respiratory, renal and hepatic functions and fluid and electrolyte balance.
Treat hypotension and arrhythmias vigorously. CNS convulsions may be treated with IV diazepam or phenytoin. Haemoperfusion may be used in severe cases.
Chlorphenamine Maleate is an antihistamine.
Chlorphenamine Maleate is an alkylamine derivative with a plasma half-life of up to 42 hours which is extensively metabolised in the liver and excreted almost exclusively in the urine.
There are no pre-clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.
Also contains: calcium sulphate, magnesium stearate, maize starch, E172, E460.
None known.
Shelf-life
Three years from the date of manufacture.
Shelf-life after dilution/reconstitution
Not applicable.
Shelf-life after first opening
Not applicable.
Store below 25°C in a dry place.
The product containers are rigid injection moulded polypropylene or injection blow-moulded polyethylene tablet containers with polyfoam wad or polyethylene ullage filler and snap-on polyethylene lids; in case any supply difficulties should arise the alternative is amber glass bottles with screw caps and polyfoam wad or cotton wool.
The product may also be supplied in blister packs in cartons:
a) Carton: Printed carton manufactured from white folding box board.
b) Blister pack: (i) 250µm white rigid PVC. (ii) Surface printed 20µm hard temper aluminium foil with 5-7g/M² PVC and PVdC compatible heat seal lacquer on the reverse side.
Pack sizes: 7, 28, 30, 50, 56, 60, 84, 90, 100, 112, 120, 168, 180, 250, 500, 1000.
Product may also be supplied in bulk packs, for reassembly purposes only, in polybags contained in tins, skillets or polybuckets filled with suitable cushioning material. Bulk packs are included for temporary storage of the finished product before final packaging into the proposed marketing containers.
Maximum size of bulk packs: 50,000.
Not applicable.
Name or style and permanent address of registered place of business of the holder of the Marketing Authorisation:
Actavis UK Limited
(Trading style: Actavis)
Whiddon Valley
BARNSTAPLE
N Devon EX32 8NS
PL 0142/0209
9.5.86
Renewed: 20.10.02
June 2007
Terbinafina Ratiopharm may be available in the countries listed below.
Terbinafine is reported as an ingredient of Terbinafina Ratiopharm in the following countries:
International Drug Name Search
Vecural may be available in the countries listed below.
Vecuronium Bromide is reported as an ingredient of Vecural in the following countries:
International Drug Name Search
Teobid may be available in the countries listed below.
Theophylline is reported as an ingredient of Teobid in the following countries:
International Drug Name Search
Tamizam may be available in the countries listed below.
Tamoxifen citrate (a derivative of Tamoxifen) is reported as an ingredient of Tamizam in the following countries:
International Drug Name Search
